☰

Alan A. Pourpak, Ph.D. - Publications

Affiliations: 
2006 University of Arizona, Tucson, AZ 
Area:
Pharmacology
Tree Info Similar researchers PubMed Report error

5 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2009 Meyers RO, Lambert JD, Hajicek N, Pourpak A, Kalaitzis JA, Dorr RT. Synthesis, characterization, and anti-melanoma activity of tetra-O-substituted analogs of nordihydroguaiaretic acid. Bioorganic & Medicinal Chemistry Letters. 19: 4752-5. PMID 19615898 DOI: 10.1016/J.Bmcl.2009.06.063  0.593
2008 Congdon LM, Pourpak A, Escalante AM, Dorr RT, Landowski TH. Proteasomal inhibition stabilizes topoisomerase IIalpha protein and reverses resistance to the topoisomerase II poison ethonafide (AMP-53, 6-ethoxyazonafide). Biochemical Pharmacology. 75: 883-90. PMID 18062937 DOI: 10.1016/J.Bcp.2007.10.026  0.564
2007 Pourpak A, Landowski TH, Dorr RT. Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells. The Journal of Pharmacology and Experimental Therapeutics. 321: 1109-17. PMID 17351106 DOI: 10.1124/Jpet.106.117457  0.616
2007 Pourpak A, Dorr RT, Meyers RO, Powell MB, Stratton SP. Cytotoxic activity of Apomine is due to a novel membrane-mediated cytolytic mechanism independent of apoptosis in the A375 human melanoma cell line. Investigational New Drugs. 25: 107-14. PMID 17024575 DOI: 10.1007/S10637-006-9015-6  0.596
2006 Pourpak A, Meyers RO, Samulitis BK, Sherry Chow HH, Kepler CY, Raymond MA, Hersh E, Dorr RT. Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice. Anti-Cancer Drugs. 17: 1179-84. PMID 17075317 DOI: 10.1097/01.Cad.0000236305.43209.F0  0.584
Show low-probability matches.